An Open Label Clinical Study to Evaluate the Safety and Efficacy of Hemp Seed Oil

amrata Hempco Limited0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年5月29日

研究概览

暂无简介。

•1.Male and female subjects with epilepsy history, ranging in age from 18 to 45 years.
•2.Willingness to follow the protocol requirements as evidenced by written, informed consent.
•3.Mentally, physically and legally eligible to give informed consent
•4.Willingness to complete study questionnaires

•1.Patients with pre-existing other severe systemic disease necessitating long-term medication.
•2.Significant medical or psychiatric illness
•3.History of cancer, including solid tumors, hematologic malignancies and carcinoma in situ
•4.Any vascular or systemic disorder which could affect any of the efficacy assessments
•5.Participation in the current or previous treatment with any approved or investigational health supplement(s) during the past 1 month
•6.Subjects received other medication (anti-viral) within the 36 hours before entry into the study
•7.Patients who had immunization against influenza or influenza like illnesses for that season.
•8.Inability to comply with the study protocol, including psychiatric diseases
•9.Immune compromised or with other clinically active illness including cardiac or pulmonary diseases, hemoglobinopathies, renal dysfunction
•10.Having vaccination of a seasonal or new influenza A (H1N1) vaccine 6 months before
•11.Other reasons that researchers think not fitting to participate in the study
•12.Evidence of significant uncontrolled comorbid disease which in the investigator opinion would jeopardize patient participation
•13.Patient tested positive with Covid 19

发起方

amrata Hempco Limited